Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo

Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo

Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patien

Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patien

Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablativ e conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients

Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablativ e conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients

Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients

Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients

Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients

Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients

Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients

Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients

Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy

Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Development of a next generation allogeneic CAR-T cell platform without gene editing

Development of a next generation allogeneic CAR-T cell platform without gene editing

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients